Elotuzumab

As a large IgG1 antibody, elotuzumab is cleared by reticuloendothelial proteolysis, not renal filtration, and does not concentrate in or injure the nephron; its serum exposure is unchanged in severe renal impairment and dialysis. It carries no intrinsic tubular, glomerular, or crystal toxicity. Electrolyte or renal abnormalities seen during therapy are attributable to the underlying plasma-cell disorder (light-chain cast nephropathy, hypercalcemia), to the renally-cleared immunomodulatory partner (lenalidomide), or to infusion reactions — not to elotuzumab. The only elotuzumab-attributable renal risk is therefore indirect and prerenal: a transient, hemodynamic effect if a severe infusion reaction drops blood pressure, which is why it sits — like the anti-CD38 myeloma antibodies (daratumumab, isatuximab) — in the prerenal/kidney-neutral category rather than carrying any direct nephrotoxic lesion. It deepens disease control that can itself improve myeloma-related renal function.

No drug-specific renal syndrome. Infusion reactions are the main acute toxicity (largely grade 1-2, mitigated by premedication). Any creatinine rise or electrolyte disturbance should be traced to myeloma activity, the partner immunomodulator, or intercurrent causes rather than to elotuzumab.

No elotuzumab-specific renal dose change is required, including in dialysis. Manage infusion reactions per protocol; address renal events through the underlying myeloma and the renally-cleared partner agents.Lesion-level management framework

No dose adjustment for any degree of renal impairment, including severe impairment and end-stage renal disease on dialysis (Berdeja 2015). The actionable renal adjustment is to the partner immunomodulator, not to elotuzumab.

A ~150 kDa IgG1 antibody — not removed by hemodialysis and cleared by proteolysis; pharmacokinetics are unchanged in dialysis patients, so no peri-dialysis timing change is needed.

A creatinine rise on an elotuzumab regimen is far more likely myeloma cast nephropathy, hypercalcemia, or lenalidomide effect than antibody toxicity; serum free light chains, calcium, and urinalysis help distinguish disease relapse from drug effect.